NPH is in an unusual situation for a Vulture exchange stock. There are no similar stocks going into the generic market in Canada to compare with so you have to look at the established companies and take it from there. It seems the mentality of the Vulture does not understand this stock and are treating it like the other carrion but that will end one day. It takes some DD to appreciate what this company is doing, to understand that the CEO has successfully done this before and what the potential cash flow is. Also some consideration should also be given to the secured DEL license to import patented prescription market as RX does. If you have no clue where this is could go then check out RX to help understand the potential of the DEL license. NPH has ordered 30 drugs so far and are carrying out their plan. Cash flow should start in the 2nd quarter. The CEO has done this before and he is doing it again.